Dan Spencer’s Post

Eli Lilly’s retatrutide emerge as a game-changer in obesity treatment? 💊 The investigational triple agonist #retatrutide is set to have a potential phase 3 readout in 2026. Phase 2 data from the American Diabetes Association Scientific Sessions in June 2023 revealed promising results - adults with obesity who received the highest dose of retatrutide lost an average of 24.2% of their body weight at 48 weeks compared with placebo 💊 Moreover, #treatment with retatrutide showed significant improvements in cardiometabolic measures. If these results are confirmed in a larger phase 3 study, it could #revolutionize obesity treatment ---------------------------------------------------------------------------------- Schedule a no-obligation consultation with EOS Intelligence to explore how we can be your partner in delivering strategic insights for a winning obesity treatment strategy Eli Lilly and Company Novo Nordisk #obesity #healthcareinnovation #perspectives #eointelligence

https://lnkd.in/ea2R6Yw3 A couple of news features caught my attention recently. First, a European study concluding that overweight and obese people are significantly more likely to take time off work because they are ill than colleagues who are a healthy weight. Second, research suggesting that "obesity jabs could cut the risk of heart attacks and strokes in people even if they fail to lose much weight, according to an analysis of a study funded by a drug manufacturer." Whilst medication may have an important role to play in tackling obesity in some cases, I think it would be inappropriate to see this as a panacea for the sickness absence problem, and more focus needs to be placed on preventing the problem 'upstream' rather than treating it 'downstream'. A statement from the Professor who led the study into the efficacy of 'obesity jabs' also caught my eye: "We now have this class of drugs which could....transform many chronic diseases of ageing..." Is the ageing process really the cause of chronic disease, or is chronic disease attributable to the lifestyle choices and health behaviours that we choose along the way....?

Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial In patients treated with semaglutide, weight loss continued over 65 weeks and was sustained for up to 4 years. At 208 weeks, semaglutide was associated with mean reduction in weight (−10.2%), waist circumference (−7.7 cm) and waist-to-height ratio (−6.9%) versus placebo (−1.5%, −1.3 cm and −1.0%, respectively; P < 0.0001 for all comparisons versus placebo). Clinically meaningful weight loss occurred in both sexes and all races, body sizes and regions. Semaglutide was associated with fewer serious adverse events. For each BMI category (<30, 30 to <35, 35 to <40 and ≥40 kg m−2) there were lower rates (events per 100 years of observation) of serious adverse events with semaglutide (43.23, 43.54, 51.07 and 47.06 for semaglutide and 50.48, 49.66, 52.73 and 60.85 for placebo). Semaglutide was associated with increased rates of trial product discontinuation. Discontinuations increased as BMI class decreased. In SELECT, at 208 weeks, semaglutide produced clinically significant weight loss and improvements in anthropometric measurements versus placebo. ** Weight loss was sustained over 4 years ** ClinicalTrials.gov identifier: NCT03574597. In the semaglutide group, 12.0% of patients achieved normal weight status at week 104 (from 0% at baseline), compared with 1.2% (from 0% at baseline) for placebo. BMI classes: healthy (BMI <25 kg m−2), overweight (25 to <30 kg m−2), class I obesity (30 to <35 kg m−2), class II obesity (35 to <40 kg m−2) and class III obesity (BMI ≥40 kg m−2). #longtermweightloss #semaglutide #evidencebased #research #SELECTTrial #weightmanagement #obesitymedicine #advocacy #metabolicdisease https://lnkd.in/gM9Sh_bD

𝗕𝗲𝘆𝗼𝗻𝗱 𝗜𝗻𝘀𝘂𝗹𝗶𝗻: 𝗛𝗼𝘄 𝗡𝗲𝘄 𝗧𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝗔𝗿𝗲 𝗖𝗵𝗮𝗻𝗴𝗶𝗻𝗴 𝘁𝗵𝗲 𝗙𝘂𝘁𝘂𝗿𝗲 𝗳𝗼𝗿 𝗗𝗶𝗮𝗯𝗲𝘁𝗲𝘀 𝗣𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝗪𝗼𝗿𝗹𝗱𝘄𝗶𝗱𝗲 Diabetes affects over 𝟱𝟬𝟬 𝗺𝗶𝗹𝗹𝗶𝗼𝗻 𝗽𝗲𝗼𝗽𝗹𝗲 globally, costing approximately $85 billion per year. By 2045, it’s projected that 𝟭 𝗶𝗻 𝟴 𝗽𝗲𝗼𝗽𝗹𝗲 will have diabetes, as its prevalence continues to rise alongside growing rates of obesity and overweight – major risk factors for Type 2 diabetes. Today, on 𝗪𝗼𝗿𝗹𝗱 𝗗𝗶𝗮𝗯𝗲𝘁𝗲𝘀 𝗗𝗮𝘆, we’re reminded of the drastic public health impact of this rising epidemic, which leads to severe complications ranging from cardiovascular disease to kidney failure. Diabetes mostly involves a dysfunction in insulin production or increased insulin resistance. To manage such condition, diabetes patients require a daily supply of insulin. However, only a handful of pharmaceutical companies produce insulin globally, leading to two critical challenges: 𝗜𝗻𝗰𝗿𝗲𝗮𝘀𝗶𝗻𝗴 𝗜𝗻𝘀𝘂𝗹𝗶𝗻 𝗥𝗲𝘀𝗶𝘀𝘁𝗮𝗻𝗰𝗲: Over time, patients on insulin therapy can develop resistance, requiring ever-higher doses to achieve the same metabolic effect. This demand progression drives up healthcare costs significantly.  𝗥𝗲𝗱𝘂𝗰𝗶𝗻𝗴 𝗦𝘂𝗽𝗽𝗹𝘆 𝗮𝗻𝗱 𝗥𝗶𝘀𝗶𝗻𝗴 𝗖𝗼𝘀𝘁𝘀: As demand for insulin grows, we’re seeing tighter supply chains and rising prices, placing an even greater burden on both individuals and healthcare systems. Yet, innovative, lasting solutions are emerging that offer hope and empowerment to patients. 𝗠𝗲𝘁𝗮𝗯𝗼𝗹𝗶𝗰 𝗶𝗻𝘁𝗲𝗿𝘃𝗲𝗻𝘁𝗶𝗼𝗻𝘀 – such as metabolic surgery or new therapies aimed at reversing insulin dependence – are reshaping diabetes management, especially for patients who are overweight or obese. Unlike daily insulin therapy, these solutions give patients the possibility of reducing or even eliminating insulin dependence in the long run, vastly improving quality of life and empowering patients to take control of their health. As we make strides in these advancements, we at @inspiring-health focus on accessible, sustainable metabolic interventions that 𝗮𝗱𝗱𝗿𝗲𝘀𝘀 𝘁𝗵𝗲 𝗿𝗼𝗼𝘁 𝗰𝗮𝘂𝘀𝗲𝘀 of diabetes and obesity, 𝗻𝗼𝘁 𝗼𝗻𝗹𝘆 𝗶𝘁𝘀 𝘀𝘆𝗺𝗽𝘁𝗼𝗺𝘀. Let’s champion technological innovations that empower patients, relieve economic burdens, and shift the trajectory of this global health movement. International Diabetes FederationWorld Health Organization 💙 #WorldDiabetesDay #DiabetesAwareness #PublicHealth #DiabetesPrevention #QualityOfLife #HealthcareInnovation #PatientEmpowerment 

AMRA is Gearing Up For ObesityWeek® 2024! We’re excited to see you all in San Antonio, TX  for The Obesity Society’s 2024 edition of ObesityWeek®, which is set to kick off this Sunday! ObesityWeek®, which runs until November 6, is the global home of the latest developments in evidence-based obesity science. The event brings together researchers, clinicians, drug developers, and policy experts to help move the obesity field forward, and AMRA is proud to share our latest findings in the field at this important event. AMRA researchers will be presenting results from a recent study that unraveled hidden weight gain, adverse muscle composition, and cardiometabolic risk increases in antidepressant users. The study, which is part of the CoMorMent Initiative, was recently published in Obesity as an “Editor’s Choice” piece. You can learn more about the study by finding our poster no. 133 titled ‘Hidden Weight Gain, Adverse Muscle Composition and Cardiometabolic Risks in Antidepressant Users’ during the session on November 3rd at 07.30 CDT. Come connect with us at OW2024, or reach out to us at info@amramedical.com to learn more. We hope to see you in the Lone Star State next week! #AMRAMedical #OW2024 #goteamAMRA #bodycomposition #musclecomposition #obesity #weightloss #GLP1 #clinicaltrials #CoMorMent

Our team was inspired by our time at #HLTH2024 and energized by the enthusiasm for our space, but with that also came the proliferation of misinformation specific to obesity medicine and GLP-1s. It is our job as leaders to hold each other accountable and dispel any false claims. At Wondr Health, we are committed to providing information that is backed by science and in the best interest of our participants and partners. With that, we would like to tackle a few misconceptions heard at HLTH and shine a light on bias when it comes to obesity medicine. MISCONCEPTION 1: Drug holidays can be beneficial for GLP-1s.  There was a lot of chatter about GLP-1 “drug holidays” - when someone intentionally stops taking their medication for a period of time. Common reasons for these treatment breaks include decreasing side effects, reducing tolerance, or to evaluating progress and determining the next course of treatment – NOT cost containment. A strong word of caution when considering “drug holidays” - obesity is a chronic condition similar to hypertension and diabetes. You wouldn’t take a drug holiday from your hypertension or diabetes medicine, would you? Why would it be any different with weight loss? Medication breaks aren’t something to be taken lightly – one study found that semaglutide recipients regained two-thirds of their lost weight within 12 months of stopping treatment. Curious about other misconceptions we saw? Stay tuned for our upcoming blog next week, where we will address more misconceptions and discuss practical, sustainable care solutions or take a look at our Chief Growth Officer, {{linkedin_mention(urn:li:person:BquL4oYI_s|Margot Case)}}’s HLTH insights here: https://lnkd.in/eVaQwpWY  

From novel drug targets to innovative combination therapies, the obesity treatment landscape is rapidly evolving. Uncover the potential game-changers in obesity management - download our article for exclusive pipeline insights. https://bit.ly/3zg1X6i #PipelineLink #TrialLink #ObesityResearch #obesitytreatment

When employers, consultants, and partners are in need of a clinically-grounded and proven cardiometabolic partners more than ever....they're getting many revenue-hungry vendors throwing science to the wind in favor of fatter balance sheets. Wondr Health is committed to providing information that is backed by science and in the best interest of our participants and partners. Whether you are an employer: 1. Interested in a "real world" behavioral, weight management program 2. Who's decided NOT TO COVER GLP-1s, but want to provide your people with clinical support 3. Who's decided TO COVER GLP-1s and want to make sure the right people, are taking the right meds, for the right reason Wondr is dedicated to being your unwavering, clinical and employer-focused partner to help navigate these ever-changing waters; together.

🚨Study Reveals Tirzepatide Outperforms Semaglutide for Weight Loss 🚨 A recent study published in The Lancet has made waves in the world of weight loss treatments. Researchers found that Tirzepatide significantly outperforms Semaglutide in helping individuals lose weight. 🔬 Key Findings: Tirzepatide led to greater weight loss compared to Semaglutide in patients with obesity, shedding up to 22.5% of their body weight in one year. In comparison, Semaglutide helped patients lose an average of 15.3% of their body weight in the same period. Both medications belong to the GLP-1 receptor agonist class, but Tirzepatide also targets another receptor (GIP), making it more effective for weight management. 💡 This breakthrough has the potential to offer even more significant benefits for those struggling with obesity and related conditions. While both medications are approved for chronic weight management, Tirzepatide may now take the lead as a more effective option. 📚 For more details, check out the full study here: https://lnkd.in/gRHBsZMU #WeightLoss #Tirzepatide #Semaglutide #Obesity #HealthNews #Mounjaro #Wegovy #Ozempic #GLP1ReceptorAgonist

🚨 𝗣𝗮𝗻𝗲𝗹 𝗔𝗹𝗲𝗿𝘁: 𝗘𝘅𝗽𝗹𝗼𝗿𝗶𝗻𝗴 𝘁𝗵𝗲 𝗣𝗿𝗼𝘀 𝗮𝗻𝗱 𝗖𝗼𝗻𝘀 𝗼𝗳 𝗗𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝘁 𝗚𝗟𝗣-𝟭 𝗗𝗿𝘂𝗴 𝗖𝗼𝗺𝗯𝗶𝗻𝗮𝘁𝗶𝗼𝗻𝘀! 🚨 Join us at the 𝗢𝗯𝗲𝘀𝗶𝘁𝘆 & 𝗠𝗲𝘁𝗮𝗯𝗼𝗹𝗶𝗰 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗙𝗼𝗿𝘂𝗺, where our expert panellists will explore the diverse potential of 𝗚𝗟𝗣-𝟭 𝗱𝗿𝘂𝗴 𝗰𝗼𝗺𝗯𝗶𝗻𝗮𝘁𝗶𝗼𝗻𝘀 in obesity treatment. 🔍 𝗣𝗮𝗻𝗲𝗹 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀: - Dive deep into GLP-1 drug combinations, comparing the unique benefits and challenges of GIP agonism vs. antagonism. - Analyse clinical data on efficacy, safety, and patient outcomes for each combination. - Understand how these approaches are shaping the broader landscape of obesity and metabolic disorder treatments. 🎙️ 𝗙𝗲𝗮𝘁𝘂𝗿𝗶𝗻𝗴:  Disha Narang, M.D., Dipl of ABOM, CCMS, Director of Obesity Medicine, Endeavour Health Group  David Tingley, Founder, Olio Labs (YC23) Eric Morgen, Co-Founder & COO, BioAge Labs 📅 𝗗𝗲𝗰𝗲𝗺𝗯𝗲𝗿 𝟰, 𝟮𝟬𝟮𝟰 👉 𝗥𝗘𝗚𝗜𝗦𝗧𝗘𝗥 to gain valuable insights into the future of obesity therapies! https://lnkd.in/edmGq6qW #ObesityInnovation #GLP1Therapies #MetabolicHealth #HealthcareLeadership #JoinTheConversation